Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy

被引:228
作者
Bozzetti, F. [1 ]
机构
[1] Univ Milan, Fac Med, Via Festa del Perdono 7, I-20122 Milan, Italy
关键词
sarcopenia; cancer and sarcopenia; sarcopenia and prognosis; sarcopenia and toxicity; sarcopenia and chemotherapy; sarcopenia therapy; SKELETAL-MUSCLE MASS; BREAST-CANCER PATIENTS; INDEPENDENT PROGNOSTIC-FACTOR; BODY-COMPOSITION PARAMETERS; CELL LUNG-CANCER; ADVANCED COLORECTAL-CANCER; DOSE-LIMITING TOXICITY; QUALITY-OF-LIFE; NUTRITIONAL-STATUS; WEIGHT-LOSS;
D O I
10.1093/annonc/mdx271
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Sarcopenia has recently emerged as a new condition that, independently from malnutrition, may adversely affect the prognosis of cancer patients. Purpose of this narrative review is to define the prevalence of sarcopenia in different primaries, its role in leading to chemotherapy toxicity and decreased compliance with the oncological therapy and the effect of some drugs on the onset of sarcopenia. Finally, the review aims to describe the current approaches to restore the muscle mass through nutrition, exercise and anti-inflammatory agents or multimodal programmes with a special emphasis on the results of randomized controlled trials. The examination of the computed tomography scan at the level of the third lumbar vertebra-a common procedure for staging many tumours-has allowed the oncologist to evaluate the muscle mass and to collect many retrospective data on the prevalence of sarcopenia and its clinical consequences. Sarcopenia is a condition affecting a high percentage of patients with a range depending on type of primary tumour and stage of disease. It is noteworthy that patients may be sarcopenic even if their nutritional status is apparently maintained or they are obese. Sarcopenic patients exhibited higher chemotherapy toxicity and poorer compliance with oncological treatments. Furthermore, several antineoplastic drugs appeared to worsen the sarcopenic status. Therapeutic approaches are several and this review will focus on those validated by randomized controlled trials. They include the use of omega-3-enriched oral nutritional supplements and orexigenic agents, the administration of adequate high-protein regimens delivered enterally or parenterally, and programmes of physical exercise. Better results are expected combining different procedures in a multimodal approach. In conclusion, there are several premises to prevent/treat sarcopenia. The oncologist should coordinate this multimodal approach by selecting priorities and sequences of treatments and then involving a nutrition health care professional or a physical therapist depending on the condition of the single patient.
引用
收藏
页码:2107 / 2118
页数:12
相关论文
共 180 条
  • [1] Frailty and malnutrition predictive of mortality risk in older patients with advanced colorectal cancer receiving chemotherapy
    Aaldriks, Ab A.
    van der Geest, Lydia G. M.
    Giltay, Erik J.
    le Cessie, Saskia
    Portielje, Johanneke E. A.
    Tanis, Bea C.
    Nortier, Johan W. R.
    Maartense, Ed
    [J]. JOURNAL OF GERIATRIC ONCOLOGY, 2013, 4 (03) : 218 - 226
  • [2] Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens
    Ali, Raafi
    Baracos, Vickie E.
    Sawyer, Michael B.
    Bianchi, Laurent
    Roberts, Sarah
    Assenat, Eric
    Mollevi, Caroline
    Senesse, Pierre
    [J]. CANCER MEDICINE, 2016, 5 (04): : 607 - 616
  • [3] Impact Total Psoas Volume on Short- and Long-Term Outcomes in Patients Undergoing Curative Resection for Pancreatic Adenocarcinoma: a New Tool to Assess Sarcopenia
    Amini, Neda
    Spolverato, Gaya
    Gupta, Rohan
    Margonis, Georgios A.
    Kim, Yuhree
    Wagner, Doris
    Rezaee, Neda
    Weiss, Matthew J.
    Wolfgang, Christopher L.
    Makary, Martin M.
    Kamel, Ihab R.
    Pawlik, Timothy M.
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2015, 19 (09) : 1593 - 1602
  • [4] Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients
    Anandavadivelan, Poorna
    Brismar, Torkel B.
    Nilsson, Magnus
    Johar, Asif M.
    Martin, Lena
    [J]. CLINICAL NUTRITION, 2016, 35 (03) : 724 - 730
  • [5] Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?
    Andreyev, HJN
    Norman, AR
    Oates, J
    Cunningham, D
    [J]. EUROPEAN JOURNAL OF CANCER, 1998, 34 (04) : 503 - 509
  • [6] Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma
    Antoun, S.
    Baracos, V. E.
    Birdsell, L.
    Escudier, B.
    Sawyer, M. B.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 (08) : 1594 - 1598
  • [7] Association of Skeletal Muscle Wasting With Treatment With Sorafenib in Patients With Advanced Renal Cell Carcinoma: Results From a Placebo-Controlled Study
    Antoun, Sami
    Birdsell, Laura
    Sawyer, Michael B.
    Venner, Peter
    Escudier, Bernard
    Baracos, Vickie E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) : 1054 - 1060
  • [8] Are there any benefits of exercise training in cancer cachexia?
    Argiles, Josep M.
    Busquets, Silvia
    Lopez-Soriano, Francisco J.
    Costelli, Paola
    Penna, Fabio
    [J]. JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2012, 3 (02) : 73 - 76
  • [9] Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study
    Arrieta, Oscar
    Michel Ortega, Rosa M.
    Villanueva-Rodriguez, Geraldine
    Serna-Thome, Maria G.
    Flores-Estrada, Diana
    Diaz-Romero, Consuelo
    Rodriguez, Cindy M.
    Martinez, Luis
    Sanchez-Lara, Karla
    [J]. BMC CANCER, 2010, 10
  • [10] Aslani A, 2000, CANCER-AM CANCER SOC, V88, P796, DOI 10.1002/(SICI)1097-0142(20000215)88:4<796::AID-CNCR10>3.0.CO